STOCK TITAN

TELA Bio, Inc. - TELA STOCK NEWS

Welcome to our dedicated page for TELA Bio news (Ticker: TELA), a resource for investors and traders seeking the latest updates and insights on TELA Bio stock.

TELA Bio, Inc. (NASDAQ: TELA) is a pioneering medical technology company based in Malvern, Pennsylvania, dedicated to transforming the field of soft tissue reconstruction. With a mission to provide advanced, cost-effective solutions, TELA Bio focuses on enhancing clinical outcomes by prioritizing the preservation and restoration of a patient's own anatomy.

The company offers two primary product lines: OviTex and OviTex PRS Reinforced Tissue Matrices. These products are designed to improve clinical outcomes and reduce costs in hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery. OviTex, a reinforced tissue matrix, leverages the body's natural healing response while minimizing long-term exposure to synthetic materials.

In recent developments, TELA Bio has launched LIQUIFIX, the first approved adhesive-based product for affixing mesh without penetrating patient tissue. This innovation underscores TELA Bio's commitment to providing surgeons with cutting-edge, economically viable solutions that align with modern clinical practices.

Financially, TELA Bio is experiencing significant growth. For the first quarter of 2024, the company reported a revenue increase of 39% year-over-year, reaching $16.6 million. This growth is attributed to a mature sales force, strategic product launches, and an expanding customer base. Despite operational losses, the company achieved a notable decrease in net loss, demonstrating improved financial management and operational efficiency.

Moreover, TELA Bio actively collaborates with leading surgeons to continuously innovate and address the unmet needs in soft tissue repair. The company's partnership with experts ensures that its products meet the highest standards of efficacy and safety.

For the latest updates, TELA Bio frequently hosts earnings conference calls and webcasts, providing valuable insights into its financial performance and strategic initiatives. Investors and stakeholders can access these resources via the investor section of the company's website.

In summary, TELA Bio, Inc. is a dynamic and forward-looking company poised to make significant advancements in medical technology. By combining innovation with practical solutions, TELA Bio aims to reinvigorate the soft tissue reconstruction market and provide substantial benefits to hospitals, surgeons, and patients alike.

Rhea-AI Summary

TELA Bio, Inc. (NASDAQ: TELA) announced the appointment of John Nosenzo, former Chief Commercial Officer at Bioventus Inc., to its board of directors, effective June 2, 2021. This change coincides with the departure of board member Adele Olivia, resulting in a board of seven directors, six of whom are independent. Nosenzo brings extensive healthcare marketing and sales experience, which could positively impact TELA's strategic direction. The company focuses on innovative tissue reinforcement materials for soft tissue reconstruction, aiming to improve clinical outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
management
-
Rhea-AI Summary

TELA Bio, Inc. (NASDAQ: TELA) has appointed Marissa Conrad as Vice President of Clinical and Regulatory Affairs, effective May 24, 2021. With over 16 years of experience in R&D, clinical, and regulatory roles in the medtech industry, she will oversee clinical and regulatory strategies for TELA's current and future products. CEO Antony Koblish praised her as a valuable asset, highlighting her strong track record and leadership skills. TELA Bio aims to enhance soft tissue reconstruction solutions through its innovative products, such as OviTex®.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.98%
Tags
none
-
Rhea-AI Summary

TELA Bio, Inc. (NASDAQ: TELA), a medical technology company focused on innovative tissue reinforcement materials, will participate in two investor conferences. The management will present at the UBS Global Healthcare Virtual Conference on May 24, 2021, at 8:00 AM EST. The Jefferies Virtual Healthcare Conference is scheduled for June 3, 2021, at 3:30 PM EST. Both presentations will be accessible via the company’s investor relations website. TELA Bio aims to enhance clinical outcomes in soft tissue reconstruction with its OviTex® products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.08%
Tags
conferences
Rhea-AI Summary

TELA Bio, Inc. (NASDAQ: TELA) has launched the BRAVO II study to evaluate the clinical performance of OviTex® Reinforced Tissue Matrices in robotic ventral hernia repairs. The first patient was enrolled at St. Luke's Hospital in Kansas. This study aims to enroll up to 100 subjects across seven US sites, focusing on early postoperative complications and long-term hernia recurrence. CEO Antony Koblish expressed commitment to enhancing surgical materials, while Dr. Geoffrey Slayden highlighted the advantages of using reinforced tissue matrices in robotic procedures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.34%
Tags
none
-
Rhea-AI Summary

TELA Bio, Inc. (Nasdaq: TELA) reported strong financial results for Q1 2021, achieving revenue of $5.9 million, a 58% increase from Q1 2020. Despite challenges from COVID-19, the company saw high utilization of its OviTex LPR product line, marking the highest volume quarter for these products. Gross profit remained stable at 59% of revenue. Operating expenses rose to $10.7 million, resulting in a net loss of $8.1 million for the quarter. For the full year, TELA maintains a revenue guidance of $27-30 million, reflecting a growth of 48-65% year-over-year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.24%
Tags
-
Rhea-AI Summary

TELA Bio, Inc. is set to report its first quarter financial results for the period ending March 31, 2021, on May 13, 2021. The company's management will hold a conference call and webcast at 4:30 p.m. ET to discuss these results and provide a corporate update. TELA Bio focuses on innovative tissue reinforcement materials designed for soft tissue reconstruction, aiming to offer effective biologic material repair solutions and improve clinical outcomes. The company is committed to addressing unmet needs in hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
Rhea-AI Summary

TELA Bio reported fourth quarter revenue of $5.7 million, an increase of 17% year-over-year, and full-year revenue of $18.2 million, up 18% from 2019. Gross profit for Q4 was $3.7 million (65% margin), and $11.2 million (62% margin) for the full year. Operating expenses rose to $10.4 million in Q4 and $36.5 million annually, leading to net losses of $7.8 million and $28.8 million, respectively. For 2021, TELA projects revenue between $27.0 million and $30.0 million, indicating growth of 48% to 65%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.29%
Tags
-
Rhea-AI Summary

TELA Bio, a medical technology company, has reported encouraging findings from the 12-month analysis of its BRAVO study on OviTex Reinforced Tissue Matrix for ventral hernia treatment. Out of 76 patients, only two experienced a recurrence at the surgical site, while interim results at 24 months showed no recurrences among the 51 patients followed. The results demonstrate low postoperative complications, and the data have been submitted for journal publication. TELA anticipates completing the BRAVO trial this year, highlighting OviTex's potential in hernia repair.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.14%
Tags
none
-
Rhea-AI Summary

TELA Bio, Inc. (NASDAQ: TELA), a medical technology company, will report its fourth quarter and full year 2020 financial results on March 24, 2021. The management team will host a conference call at 4:30 p.m. ET the same day to discuss these results and provide a corporate update. TELA specializes in innovative tissue reinforcement materials aimed at soft tissue reconstruction, particularly in hernia repair and abdominal wall reconstruction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
conferences earnings
Rhea-AI Summary

MALVERN, Pa., Feb. 4, 2021 - TELA Bio, a commercial-stage medical technology company, will participate in the BTIG Virtual MedTech Conference on February 18, 2021, at 4:30 PM EST. The company focuses on innovative tissue reinforcement materials for soft tissue reconstruction, aiming to enhance patient outcomes while minimizing reliance on synthetic materials. TELA's key products include OviTex® and OviTex PRS Reinforced Tissue Matrix, designed for hernia repair and reconstructive surgeries. Interested parties may access the webcast via their [investor relations page](https://ir.telabio.com).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.07%
Tags
conferences

FAQ

What is the current stock price of TELA Bio (TELA)?

The current stock price of TELA Bio (TELA) is $2.93 as of December 23, 2024.

What is the market cap of TELA Bio (TELA)?

The market cap of TELA Bio (TELA) is approximately 113.2M.

What does TELA Bio, Inc. specialize in?

TELA Bio, Inc. specializes in developing and marketing tissue reinforcement materials for soft tissue reconstruction, including hernia repair and plastic surgery.

What are the main products offered by TELA Bio?

TELA Bio's main products include OviTex and OviTex PRS Reinforced Tissue Matrices, designed to improve clinical outcomes in hernia repair and plastic surgery.

Where is TELA Bio, Inc. located?

TELA Bio, Inc. is headquartered in Malvern, Pennsylvania, United States.

How has TELA Bio performed financially recently?

In Q1 2024, TELA Bio reported a 39% increase in revenue year-over-year, reaching $16.6 million, and a reduced net loss compared to the same period in 2023.

What recent product has TELA Bio launched?

TELA Bio recently launched LIQUIFIX, an adhesive-based product for affixing mesh without penetrating patient tissue.

How can investors stay updated on TELA Bio's performance?

Investors can stay updated by accessing earnings conference calls and webcasts available on the investor section of TELA Bio's website.

What is OviTex?

OviTex is a reinforced tissue matrix developed by TELA Bio to improve clinical outcomes and reduce costs in hernia repair and abdominal wall reconstruction.

Which market needs does TELA Bio aim to address?

TELA Bio aims to address unmet needs in soft tissue repair, particularly in hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery.

Is TELA Bio publicly traded?

Yes, TELA Bio, Inc. is publicly traded on NASDAQ under the ticker symbol TELA.

Who can be contacted for investor relations at TELA Bio?

For investor relations, TELA Bio's contact is Louisa Smith, who can be reached at ir@telabio.com.

TELA Bio, Inc.

Nasdaq:TELA

TELA Rankings

TELA Stock Data

113.18M
33.31M
7.32%
51.7%
0.85%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
MALVERN